A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis
Phase 1
Active, not recruiting
- Conditions
- Osteoarthritis, Knee
- Interventions
- Genetic: ICM-203Drug: Placebo
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- ICM Biotech Australia Pty Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04875754
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Barwon Health, Geelong, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath